The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
(Reuters) – British drugmaker AstraZeneca and Japan’s Daiichi Sankyo said on Wednesday their experimental treatment for breast cancer met its key goal in a mid-stage study, bolstering their defenses in a highly competitive oncology market.
The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic breast cancer, the two companies said in a joint statement.
Reporting by Pushkala Aripaka in Bengaluru; editing by Gopakumar Warrier